America’s intellectual property (IP) system makes medicines more affordable through innovative research, brand competition and lower-cost generics.
See how.
Competition is a strong force in biopharma, challenging even the biggest companies in the sector to innovate or perish. But competition also pushes the whole industry to even greater heights. That’s the lesson Tolga Tanguler has learned as chief commercial officer at Alnylam Pharmaceuticals while launching RNAi-based medicines into a market led by a blockbuster Pfizer franchise.
Pfizer’s deep pockets gave Alnylam a leg up — by educating patients and healthcare professionals about the rare disease ATTR amyloidosis and establishing a patient pool, Alnylam had a clearer starting point when it launched a genetic medicine into that space. Ultimately, the trail Pfizer blazed has helped guide the smaller company on the market and importantly, Tanguler said, has given patients more choice.
Today, we’re featuring a conversation with Tanguler about the unique role Alnylam is playing in the rise of RNAi medicines and how the company is still pushing boundaries as it reaches into wider markets.
Thanks for reading.
Michael Gibney Senior Editor & Writer, PharmaVoice Email
Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.
Recent federal policy shifts are reshaping how life sciences organizations approach diversity initiatives in clinical research. Explore how pharma giants are refining diversity goals in R&D in this Trendline.
